RVTY
NYSE · Life Sciences Tools & Services
Revvity Inc
$101.00
+2.15 (+2.18%)
Financial Highlights (FY 2026)
Revenue
2.76B
Net Income
233.39M
Gross Margin
54.8%
Profit Margin
8.5%
Rev Growth
-4.8%
D/E Ratio
0.44
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 54.8% | 54.8% | 29.9% | 29.9% |
| Operating Margin | 12.5% | 11.2% | 6.5% | 5.7% |
| Profit Margin | 8.5% | 8.0% | 5.6% | 4.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.76B | 2.90B | 9.95B | 9.42B |
| Gross Profit | 1.51B | 1.59B | 2.98B | 2.82B |
| Operating Income | 345.18M | 326.39M | 644.83M | 535.65M |
| Net Income | 233.39M | 220.69M | 559.12M | 450.80M |
| Gross Margin | 54.8% | 54.8% | 29.9% | 29.9% |
| Operating Margin | 12.5% | 11.2% | 6.5% | 5.7% |
| Profit Margin | 8.5% | 8.0% | 5.6% | 4.8% |
| Rev Growth | -4.8% | -4.8% | +15.3% | +12.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.75B | 1.75B | 3.48B | 3.04B |
| Total Equity | 3.95B | 3.95B | 5.58B | 6.26B |
| D/E Ratio | 0.44 | 0.44 | 0.62 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 736.48M | 735.08M | 873.56M | 871.70M |
| Free Cash Flow | — | — | 503.74M | 344.62M |